Virologica Sinica

, Volume 28, Issue 3, pp 174–182 | Cite as

Immunization with cytomegalovirus envelope glycoprotein M and glycoprotein N DNA vaccines can provide mice with complete protection against a lethal murine cytomegalovirus challenge

  • Huadong Wang
  • Yanfeng Yao
  • Chaoyang Huang
  • Quanjiao Chen
  • Jianjun Chen
  • Ze Chen
Research Article


Human cytomegalovirus virions contain three major glycoprotein complexes (gC I, II, III), all of which are required for CMV infectivity. These complexes also represent major antigenic targets for anti-viral immune responses. The gC II complex consists of two glycoproteins, gM and gN. In the current study, DNA vaccines expressing the murine cytomegalovirus (MCMV) homologs of the gM and gN proteins were evaluated for protection against lethal MCMV infection in a mouse model. Humoral and cellular immune responses, spleen viral titers, and mice survival and body-weight changes were examined. The results showed that immunization with gM or gN DNA vaccine alone was not able to offer good protection, whereas co-immunization with both gM and gN induced an effective neutralizing antibody response and cellular immune response, and provided mice with complete protection against a lethal MCMV challenge. This study provides the first in vivo evidence that the gC II (gM-gN) complex may be able to serve as a protective subunit antigen for future HCMV vaccine development.


Cytomegalovirus Envelope glycoprotein complex gM/gN DNA vaccine 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aihara H, and Miyazaki J. 1998. Gene transfer into muscle by electroporation in vivo. Nat Biotechnol, 16: 867–870.PubMedCrossRefGoogle Scholar
  2. Arvin A M, Fast P, Myers M, Plotkin S, and Rabinovich R. 2004. Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee. Clin Infect Dis, 39: 233–239.PubMedCrossRefGoogle Scholar
  3. Boeckh M, and Geballe A P. 2011. Cytomegalovirus: pathogen, paradigm, and puzzle. J Clin Invest, 121: 1673–1680.PubMedCrossRefGoogle Scholar
  4. Britt W J, and Mach M. 1996. Human cytomegalovirus glycoproteins. Intervirology, 39: 401–412.PubMedGoogle Scholar
  5. Britt W J, and Boppana S. 2004. Human cytomegalovirus virion proteins. Hum Immunol, 65: 395–402.PubMedCrossRefGoogle Scholar
  6. Brune W, Hengel H, and Koszinowski U H. 2001. A mouse model for cytomegalovirus infection. Curr Protoc Immunol, Chapter 19: Unit 19 17.Google Scholar
  7. Chen J J, Huang S P, and Chen Z. 2010. Human cellular protein nucleoporin hNup98 interacts with influenza A virus NS2/nuclear export protein and overexpression of its GLFG repeat domain can inhibit virus propagation. J Gen Virol, 91: 2474–2484.PubMedCrossRefGoogle Scholar
  8. Geoffroy F, Moachon N, Rodwell J, and Quash G A. 1996. Murine cytomegalovirus inactivated by sodium periodate is innocuous and immunogenic in mice and protects them against death and infection. Vaccine, 14: 1686–1694.PubMedCrossRefGoogle Scholar
  9. Griffiths P D. 2002. The 2001 Garrod lecture. The treatment of cytomegalovirus infection. J Antimicrob Chemother, 49: 243–253.PubMedCrossRefGoogle Scholar
  10. Hobom U, Brune W, Messerle M, Hahn G, and Koszinowski U H. 2000. Fast screening procedures for random transposon libraries of cloned herpesvirus genomes: mutational analysis of human cytomegalovirus envelope glycoprotein genes. J Virol, 74: 7720–7729.PubMedCrossRefGoogle Scholar
  11. Jons A, Dijkstra J M, and Mettenleiter T C. 1998. Glycoproteins M and N of pseudorabies virus form a disulfide-linked complex. J Virol, 72: 550–557.PubMedGoogle Scholar
  12. Khanna R, and Diamond D J. 2006. Human cytomegalovirus vaccine: time to look for alternative options. Trends Mol Med, 12: 26–33.PubMedCrossRefGoogle Scholar
  13. Krzyzaniak M, Mach M, and Britt W J. 2007. The cytoplasmic tail of glycoprotein M (gpUL100) expresses trafficking signals required for human cytomegalovirus assembly and replication. J Virol, 81: 10316–10328.PubMedCrossRefGoogle Scholar
  14. Lazzarotto T, and Lanari M. 2011. Why is cytomegalovirus the most frequent cause of congenital infection? Expert Rev Anti Infect Ther, 9: 841–843.PubMedCrossRefGoogle Scholar
  15. Loomis R J, Lilja A E, Monroe J, Balabanis K A, Brito L, Palladino G, Franti M, Mandl C W, Barnett S W, and Mason P W. 2012. Vectored co-delivery of human cytomegalovirus gH and gL proteins elicits potent complement-independent neutralizing antibodies. Vaccine, 31(6):919–926.PubMedCrossRefGoogle Scholar
  16. Mach M, Kropff B, Dal Monte P, and Britt W. 2000. Complex formation by human cytomegalovirus glycoproteins M (gpUL100) and N (gpUL73). J Virol, 74: 11881–11892.PubMedCrossRefGoogle Scholar
  17. Mach M, Kropff B, Kryzaniak M, and Britt W. 2005. Complex formation by glycoproteins M and N of human cytomegalovirus: structural and functional aspects. J Virol, 79: 2160–2170.PubMedCrossRefGoogle Scholar
  18. Mach M, Osinski K, Kropff B, Schloetzer-Schrehardt U, Krzyzaniak M, and Britt W. 2007. The carboxy-terminal domain of glycoprotein N of human cytomegalovirus is required for virion morphogenesis. J Virol, 81: 5212–5224.PubMedCrossRefGoogle Scholar
  19. Manley K, Anderson J, Yang F, Szustakowski J, Oakeley E J, Compton T, and Feire A L. 2011. Human cytomegalovirus escapes a naturally occurring neutralizing antibody by incorporating it into assembling virions. Cell Host & Microbe, 10: 197–209.CrossRefGoogle Scholar
  20. Pass R F, Zhang C P, Evans A, Simpson T, Andrews W, Huang M L, Corey L, Hill J, Davis E, Flanigan C, and Cloud G. 2009. Vaccine prevention of maternal cytomegalovirus infection. New England Journal of Medicine, 360: 1191–1199.PubMedCrossRefGoogle Scholar
  21. Qureshi M H, Garvy B A, Pomeroy C, Inayat M S, and Oakley O R. 2005. A murine model of dual infection with cytomegalovirus and Pneumocystis carinii: Effects of virus-induced immunomodulation on disease progression. Virus Research, 114: 35–44.PubMedCrossRefGoogle Scholar
  22. Scalzo A A, Forbes C A, Davis-Poynter N J, Farrell H E, and Lyons P A. 1995. DNA sequence and transcriptional analysis of the glycoprotein M gene of murine cytomegalovirus. J Gen Virol, 76(Pt 11): 2895–2901.PubMedCrossRefGoogle Scholar
  23. Schleiss M R, and Heineman T C. 2005. Progress toward an elusive goal: current status of cytomegalovirus vaccines. Expert Rev Vaccines, 4: 381–406.PubMedCrossRefGoogle Scholar
  24. Shen S, Wang S, Britt W J, and Lu S. 2007. DNA vaccines expressing glycoprotein complex II antigens gM and gN elicited neutralizing antibodies against multiple human cytomegalovirus (HCMV) isolates. Vaccine, 25: 3319–3327.PubMedCrossRefGoogle Scholar
  25. Shimamura M, Mach M, and Britt W J. 2006. Human cytomegalovirus infection elicits a glycoprotein M (gM)/gN-specific virus-neutralizing antibody response. J Virol, 80: 4591–4600.PubMedCrossRefGoogle Scholar
  26. Sung H, and Schleiss M R. 2010. Update on the current status of cytomegalovirus vaccines. Expert Rev Vaccines, 9: 1303–1314.PubMedCrossRefGoogle Scholar
  27. Tandon R, and Mocarski E S. 2012. Viral and host control of cytomegalovirus maturation. Trends Microbiol, 20: 392–401.PubMedCrossRefGoogle Scholar
  28. Wang D, and Shenk T. 2005. Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc Natl Acad Sci U S A, 102: 18153–18158.PubMedCrossRefGoogle Scholar
  29. Zhong J, and Khanna R. 2007. Vaccine strategies against human cytomegalovirus infection. Expert Rev Anti Infect Ther, 5: 449–459.PubMedCrossRefGoogle Scholar

Copyright information

© Wuhan Institute of Virology, CAS and Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Huadong Wang
    • 1
    • 4
  • Yanfeng Yao
    • 1
  • Chaoyang Huang
    • 2
  • Quanjiao Chen
    • 1
  • Jianjun Chen
    • 1
  • Ze Chen
    • 1
    • 2
    • 3
  1. 1.State Key Laboratory of Virology, Wuhan Institute of VirologyChinese Academy of SciencesWuhanChina
  2. 2.College of Life ScienceHunan Normal UniversityChangshaChina
  3. 3.Shanghai Institute of Biological ProductsShanghaiChina
  4. 4.Graduate University of Chinese Academy of SciencesBeijingChina

Personalised recommendations